PB Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Psychiatry Advances in Psychiatric Treatment All RCPsych Journals
 QUICK SEARCH:   [advanced]


     


Psychiatric Bulletin (2008) 32: 174-177. doi: 10.1192/pb.bp.107.017343
© 2008 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Morgan, D.
Right arrow Articles by Hughes, G.
PubMed
Right arrow Articles by Morgan, D.
Right arrow Articles by Hughes, G.

Audit of metabolic syndrome in adults prescribed clozapine in community and long-stay in-patient populations

David Morgan, Specialty Registrar (ST4) in Forensic Psychiatry

*The Caswell Clinic, Glanrhyd Hospital, Tondu Road, Bridgend, South Wales CF314LN, email: davidw.morgan{at}bromor-tr.wales.nhs.uk

Matthew Sargeant, Medical Director and Consultant Psychiatrist, Jude Chukwuma, Specialist Registrar in General Adult Psychiatry and Gwenllian Hughes, Pharmacist

Carmarthenshire Locality, Pembrokeshire and Derwen NHS Trust, Hafan Derwen, Parc Dewi Sant, Carmarthen

Declaration of interest

D.W.M. has received honoraria from both Eli Lilly and Sanofi-Aventis.

AIMS AND METHODS

To calculate the prevalence of metabolic syndrome in patients receiving clozapine in community and long-stay in-patient settings. Patients were assessed using measures specified by the Expert Panel of the US National Cholesterol Education Program.

RESULTS

The prevalence of the metabolic syndrome was calculated as 53% in the community groups and 11% in the in-patient group, although both sample sizes (particularly the in-patient group) were small. Women were more frequently affected than men in the community population.

CLINICAL IMPLICATIONS

The higher percentage of metabolic syndrome in the community patients receiving clozapine has implications with respect to physical health. The reasons for the lower percentage in the in-patient group are unclear. Our findings point to a possible difference in the physical health of long-stay psychiatric in-patients and patients in the community.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Psychiatry Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 2008 The Royal College of Psychiatrists.